

MARUKYOU BIO FOODS Co.


Nano247

A new hypertension remedy using chondroitin sulfate oligosaccharide




What is hypertension?

Hypertension is also known as a silent killer, as it gradually damages tissues without causing any subjective symptoms, and can eventually lead to serious conditions such as cerebral infarction and myocardial infarction.



The causes of hypertension are not uniform, and are extremely diverse. Excess salt intake, obesity, arteriosclerosis, stress, etc. are all factors, but the main cause is still excessive salt intake in the diet.




1. Administration test on hypertensive model rats

Animals used	Spontaneously hypertensive rats (SHR)		
Test substance	Nano247 chondroitin sulfate oligosaccharide (Mw.2000)		
Dose	20 mg / head / day (equivalent to 800 mg / man / day in humans)		
Administration method	Mixed feed administration		
Group composition	10 test substance administration group, 6 non-administration group		
Evaluation items	Blood pressure (once every two weeks)		
Duration of administration	12 weeks (23 weeks old)		

Spontaneously hypertensive rats (SHR) are a strain of rat that develops hypertension with age without any artificial treatment, and have a genetic characteristic. Their systolic blood pressure rises to over 200.

1. Test results



The administration of CS oligosaccharides significantly suppressed the increase in systolic blood pressure.

Conclusion


Chondroitin sulfate oligosaccharides inhibit the rise in blood pressure in hypertensive model rats when administered orally.

2. Human intervention study

Test Subject Title	A placebo-controlled, randomized, double-blind, parallel-group comparative study of the effect of continuous intake of chondroitin sulfate oligosaccharide on blood pressure improvement				
Test Purpose	To investigate the effect of continuous intake of chondroitin sulfate oligosaccharide on blood pressure improvement and safety in a placebo-controlled, randomized, double-blind, parallel-group comparative study.				
Subjects	Adult men and women aged 40 to 65 years with a systolic blood pressure of 130 to 139 mmHg and a diastolic blood pressure of 89 mmHg or less at the time of visit				
Study design	Placebo-controlled, randomized, double-blind, parallel-group comparative study				
Group composition	Placebo food intake group and test food intake group (Dose: 100 mg / head / day/ human)				
Registered users	70 (35 in each group)				
Number of participants enrolled	69 (34 in the placebo food intake group, 35 in the test food intake group)				
Intake period	12 weeks				
Evaluation period	Before intake, 4 weeks after intake, 8 weeks after intake, 12 weeks after intake				
Main evaluation items	Blood pressure (systolic blood pressure, diastolic blood pressure) at the time of visit Secondary evaluation items				
Secondary evaluation items	 Blood glucose (blood glucose level, HbA1c) FMD (Flow-mediated dilatation) (only before the start of intake and 12 weeks after intake) CAVI (Cardio-ankle vascular index) (only before the start of intake and 12 weeks after intake) 				

2-1. Test results: Human intervention study: Blood pressure

(Subclass analysis: males with T-Cho of 200 or more)



Blood pressure in the CSOS group was significantly lower than in the placebo group.

2-2. Human Intervention Study: Blood Test Results

(Subclass analysis: males with T-Cho of 200 or more)

		0W	12W	差
White blood cell	Active	5,786	5,306	-480
count	Placebo	5,784	5,068	-716
Red blood cell	Active	492	482	-10
count	Placebo	477	473	-4
Hemoglobin level	Active	15.1	14.7	0
	Placebo	13.2	13.1	0
hematocrit	Active	45	45	0
	Placebo	45	45	0
MCV	Active	92	94	2
IVICV	Placebo	95	95	0
MCH	Active	30.7	30.4	0
IVICII	Placebo	31.8	31.7	0
MCHC	Active	33.3	32.4	-1
IVICITO	Placebo	33.4	33.2	0
Platelet count	Active	26.6	25.2	-1
	Placebo	25.3	23.1	-2 0
TP	Active	7.3	7.1	0
I	Placebo	7.4	7.1	0
ALB_BCP	Active	4.5	4.4	0
ALD_DCF	Placebo	4.6	4.4	0
T_Bil	Active	0.6	0.7	0
I_DII	Placebo	0.8	0.8	0
ALP	Active	69.5	68.0	-2
ALP	Placebo	75.5	73.9	-2 -2
LD	Active	175.3	173.4	-2
LU	Placebo	197.0	191.8	-5

項目	treat	0W	12W	差
ACT	Active	21.6	21.7	0
AST	Placebo	22.1	24.4	2
A I T	Active	21.6	21.0	-1
ALT	Placebo	18.8	20.3	2
« CT	Active	28.7	29.8	1
g_GT	Placebo	51.0	45.8	-5
CK -	Active	153.9	118.1	-36
CN	Placebo	133.6	149.0	15
T-Cho	Active	231.3	230.8	-1
1-0110	Placebo	224.1	226.5	2 7
neutral fat	Active	123.5	130.3	7
	Placebo	120.1	125.5	<u>5</u> -2
HDL_C	Active	66.1	64.1	
TIDE_C	Placebo	66.8	63.6	-3 0
LDL_C	Active	142.8	142.8	0
LDL_C	Placebo	136.8	140.9	4
urea nitrogen	Active	13.8	13.5	0
urea miliogen	Placebo	13.0	15.3	2
Creatinine	Active	0.8	0.9	0
Creatiffile	Placebo	0.8	0.8	0
UA	Active	5.9	6.1	0
<u> </u>	Placebo	6.3	6.5	0
blood sugar_fasting	Active	98.9	97.4	-2
	Placebo	103.0	99.3	-4
HbA1c_NGSP	Active	5.5	5.6	0
	Placebo	5.3	5.4	0

Chondroitin sulfate oligosaccharides significantly reduce blood CK levels.

Conclusion

Chondroitin sulfate oligosaccharides suppress hypertension in humans when taken orally

and their effects can be measured using blood markers.

chondroitin sulfate oligosaccharides

Oral intake

intestinal absorption

Blood flow

To all tissue cells

Suppression of CK gene expression

Decrease in CK activity in the organization

Inhibition of Na reabsorption in the kidney

Decrease in water reabsorption

Absorbed directly through the intestinal tract

Transfer into the bloodstream.

<u>Transported to all tissues of the body by blood flow.</u>

Suppresses the expression of the creatine kinase gene in cells

The creatine kinase activity of the tissue is decreased.


Decreased activity of Na/K ATPase in the kidney

In the kidneys, the amount of water reabsorbed for dilution of Na decreases

Blood pressure suppression

3. Supplementary data: Verification in Cell Tests

Amount of creatine kinase gene expression in cultured cells



3. Supplementary data: Verification in animal tissue (hypertension model rats)

Amount of creatine kinase gene expression in rat kidneys

